Hospital
DLP Haywood Regional Medical Center LLC.
DLP Haywood Regional Medical Center LLC. was paid $8.78M by Medicaid between Jan 2018 and Dec 2024, across 108 billing codes. Its largest line is 99285, emergency room visit (most serious) — 27% of everything it billed.
33Billing provider infoDLP HAYWOOD REGIONAL MEDICAL CENTER LLC.
CLYDE, NC 28721
CLYDE, NC 28721
33aNPI1811158215assigned 06/19/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.78M
24GClaims222,450
24DCodes billed108
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#55 of 92
Median peer was paid$11.47M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,243 | $928K | |
| 2019 | 32,404 | $882K | |
| 2020 | 20,008 | $434K | |
| 2021 | 27,522 | $1.03M | |
| 2022 | 33,637 | $1.59M | |
| 2023 | 41,144 | $1.96M | |
| 2024incomplete | 33,492 | $1.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 27% | 14,280 | 11,826 | $2.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 11,578 | 9,925 | $1.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 14,276 | 12,200 | $1.26M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.6% | 25,187 | 21,151 | $669K |
| 87428 | 5.4% | 6,434 | 5,803 | $472K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.9% | 9,213 | 7,894 | $256K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 7,721 | 6,463 | $221K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 1,565 | 1,279 | $207K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.8% | 7,774 | 5,983 | $157K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.6% | 9,624 | 8,256 | $141K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 1,655 | 1,390 | $135K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 18,860 | 16,419 | $132K |
96 more codes
| 80053 | Comprehensive metabolic panel | 1.4% | 16,070 | $121K |
| 97597 | 1.1% | 1,303 | $93K | |
| 99203 | Doctor's office visit, new patient (routine) | 1.0% | 3,540 | $90K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 5,916 | $89K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,340 | $86K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,483 | $85K |
| 87631 | <1% | 953 | $73K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,509 | $72K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,396 | $58K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,483 | $46K |
| 87081 | <1% | 4,968 | $42K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,842 | $41K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,179 | $40K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 983 | $30K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,287 | $29K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,265 | $29K |
| 80306 | <1% | 744 | $27K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,051 | $26K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 809 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,830 | $25K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 905 | $22K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,256 | $21K |
| 83690 | <1% | 2,768 | $18K | |
| 81001 | <1% | 5,652 | $17K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 31 | $16K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 172 | $15K |
| 84484 | <1% | 1,808 | $15K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,780 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 617 | $13K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,318 | $12K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 163 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 190 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 242 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 419 | $9K |
| 84702 | <1% | 758 | $7K | |
| 87807 | <1% | 427 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 21 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 84 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 150 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 55 | $5K |
| 83735 | <1% | 872 | $5K | |
| 87070 | <1% | 473 | $5K | |
| 81003 | <1% | 1,960 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,894 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 92 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,158 | $4K |
| 84703 | <1% | 422 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 167 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 147 | $3K |
| 82962 | <1% | 734 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,032 | $3K |
| 80061 | Lipid panel | <1% | 141 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 627 | $2K |
| 88142 | <1% | 119 | $2K | |
| 99201 | <1% | 181 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 657 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 70 | $2K |
| 93970 | <1% | 14 | $1K | |
| 80055 | <1% | 44 | $1K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 35 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 85 | $1K |
| 87186 | <1% | 88 | $846.00 | |
| 86803 | <1% | 46 | $834.62 | |
| 86780 | <1% | 41 | $712.94 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 60 | $643.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 438 | $579.57 |
| 87653 | <1% | 14 | $548.45 | |
| 72110 | <1% | 12 | $532.55 | |
| 87899 | <1% | 28 | $463.99 | |
| 82565 | <1% | 124 | $460.69 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 55 | $452.71 |
| 82105 | <1% | 12 | $373.51 | |
| 84145 | <1% | 15 | $337.87 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $299.20 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 547 | $294.25 |
| 81025 | <1% | 42 | $267.92 | |
| 82951 | <1% | 14 | $237.84 | |
| 86787 | <1% | 15 | $192.60 | |
| 86702 | <1% | 16 | $167.50 | |
| J3490 | Unclassified drugs | <1% | 173 | $144.30 |
| 86308 | <1% | 15 | $128.53 | |
| 86701 | <1% | 16 | $126.48 | |
| 85610 | <1% | 64 | $115.60 | |
| 83605 | <1% | 66 | $99.69 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 57 | $90.81 |
| 85652 | <1% | 29 | $53.86 | |
| 85651 | <1% | 31 | $49.66 | |
| 85730 | <1% | 12 | $15.70 | |
| 84450 | <1% | 67 | $7.48 | |
| 84460 | <1% | 68 | $0.55 | |
| 82746 | 0% | 16 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 137 | $0.00 |
| 82607 | 0% | 16 | $0.00 | |
| 80305 | 0% | 217 | $0.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.